http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-118639-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdc2787a32cce910a72605c3d3b8133c |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19e0a2f32a3785f090020babe5b8eafe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4463efe91fc749ef4b878d26a7f6ca9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_306ced082ef5019c26e24955215e8ac0 |
| publicationDate | 2021-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-118639-A1 |
| titleOfInvention | COMPOSITIONS AND METHODS FOR TREATING DISEASES MEDIATED BY KIT AND PDGFRA |
| abstract | The present disclosure provides compounds of formula (1), pharmaceutical salts thereof, and / or solvates of any of the foregoing, which are useful for treating diseases and conditions related to PDGFRa and mutant KIT and exhibit an advantageous non-penetrating profile. brain to treat diseases and conditions related to PDGFRa and mutant KIT. The present disclosure also provides a method for treating gastrointestinal stromal tumors and systemic mastocytosis. Claim 1: A compound of formula (1), a pharmaceutically acceptable salt thereof, and / or a solvate of any of the foregoing, where: A is a compound of formula (2); R¹ is selected from hydrogen and methyl; R² is selected from hydrogen and methyl; or R¹ and R² taken together form a cyclopropyl; R³ is selected from hydrogen and methyl; R⁴ is selected from hydrogen and methyl; or R³ and R⁴ taken together form a cyclopropyl; R⁵ is selected from hydrogen and methyl; R⁶ is selected from hydrogen and methyl; or R⁵ and R⁶ taken together form a cyclopropyl, or one or R² or R⁴ taken together with R⁶ forms a cyclobutyl; R⁷ is hydrogen, or one of R², R⁴, or R⁶ taken together with R⁷ forms a ring selected from oxetane, tetrahydrofuran, and tetrahydropyran, wherein said tetrahydrofuran or tetrahydropyran is optionally substituted with hydroxyl; m is 0 or 1; and n is 0 or 1. |
| priorityDate | 2019-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.